These discoveries have significantly advanced the development of targeted treatments, such as biologic therapies that block specific pro-inflammatory cytokines like IL-17 and IL-23, offering more effective and personalized treatment options for patients with psoriasis and IBD​ [7]. Here, IL17A is linked to inflammatory bowel disease.